₹ 1,308.68 Cr
2.1%
NIFTY Pharma TRI
INF277K018A5
5000.0
1000.0
100
Meeta Shetty, Rajat Srivastava
Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
---|---|---|---|
TATA India Pharma & Healthcare Fund Regular Plan - Reinvestment of Income Distribution cum Capital Withdrawal option | -2.95 | 21.94 | 17.22 |
Nifty Pharma TRI | -6.84 | 20.8 | 13.97 |
Equity
Debt
Others
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Company | Holdings (%) |
---|---|
SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 9.94 |
CIPLA LIMITED EQ NEW FV RS.2/- | 6.92 |
APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 5.15 |
HEALTHCARE GLOBAL ENTERPRISES LTD EQ | 4.85 |
LUPIN LIMITED EQ NEW F.V. RS.2/- | 4.79 |
TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 4.58 |
ASTER DM HEALTHCARE LIMITED EQ | 4.4 |
ALKEM LABORATORIES LIMITED EQ | 4.31 |
MAX HEALTHCARE INSTITUTE LIMITED EQ | 4.05 |
DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 3.9 |
Sector | Holdings (%) |
---|---|
Healthcare | 93.41 |
Financial Services | 1.83 |
Chemicals | 1.44 |
Consumer Services | 0.76 |